698 related articles for article (PubMed ID: 26455339)
1. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
Garidel P; Pevestorf B; Bahrenburg S
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
[TBL] [Abstract][Full Text] [Related]
2. Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications.
Bahrenburg S; Karow AR; Garidel P
Biotechnol J; 2015 Apr; 10(4):610-22. PubMed ID: 25641961
[TBL] [Abstract][Full Text] [Related]
3. Self-buffering antibody formulations.
Gokarn YR; Kras E; Nodgaard C; Dharmavaram V; Fesinmeyer RM; Hultgen H; Brych S; Remmele RL; Brems DN; Hershenson S
J Pharm Sci; 2008 Aug; 97(8):3051-66. PubMed ID: 18023013
[TBL] [Abstract][Full Text] [Related]
4. Excipients for Room Temperature Stable Freeze-Dried Monoclonal Antibody Formulations.
Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
J Pharm Sci; 2020 Jan; 109(1):807-817. PubMed ID: 31622600
[TBL] [Abstract][Full Text] [Related]
5. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
Cleland JL; Lam X; Kendrick B; Yang J; Yang TH; Overcashier D; Brooks D; Hsu C; Carpenter JF
J Pharm Sci; 2001 Mar; 90(3):310-21. PubMed ID: 11170024
[TBL] [Abstract][Full Text] [Related]
6. Impact of dextran on thermal properties, product quality attributes, and monoclonal antibody stability in freeze-dried formulations.
Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
Eur J Pharm Biopharm; 2020 Feb; 147():45-56. PubMed ID: 31866444
[TBL] [Abstract][Full Text] [Related]
7. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
Santana H; García G; Vega M; Beldarraín A; Páez R
PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
[TBL] [Abstract][Full Text] [Related]
8. The effects of formulation variables on the stability of freeze-dried human growth hormone.
Pikal MJ; Dellerman KM; Roy ML; Riggin RM
Pharm Res; 1991 Apr; 8(4):427-36. PubMed ID: 1871037
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking.
Jin MJ; Ge XZ; Huang Q; Liu JW; Ingle RG; Gao D; Fang WJ
Pharm Res; 2024 Feb; 41(2):321-334. PubMed ID: 38291165
[TBL] [Abstract][Full Text] [Related]
11. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
[TBL] [Abstract][Full Text] [Related]
12. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray-drying: Trehalose/amino acid combinations as reconstitution time reducing and stability improving formulations.
Massant J; Fleurime S; Batens M; Vanhaerents H; Van den Mooter G
Eur J Pharm Biopharm; 2020 Nov; 156():131-142. PubMed ID: 32882422
[TBL] [Abstract][Full Text] [Related]
13. Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist.
Chang BS; Reeder G; Carpenter JF
Pharm Res; 1996 Feb; 13(2):243-9. PubMed ID: 8932444
[TBL] [Abstract][Full Text] [Related]
14. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls.
Batens M; Massant J; Teodorescu B; Van den Mooter G
Eur J Pharm Biopharm; 2018 Jun; 127():407-422. PubMed ID: 29499299
[TBL] [Abstract][Full Text] [Related]
15. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
[TBL] [Abstract][Full Text] [Related]
16. Investigation of histidine stabilizing effects on LDH during freeze-drying.
Al-Hussein A; Gieseler H
J Pharm Sci; 2013 Mar; 102(3):813-26. PubMed ID: 23280685
[TBL] [Abstract][Full Text] [Related]
17. Significant Drying Time Reduction Using Microwave-Assisted Freeze-Drying for a Monoclonal Antibody.
Gitter JH; Geidobler R; Presser I; Winter G
J Pharm Sci; 2018 Oct; 107(10):2538-2543. PubMed ID: 29890173
[TBL] [Abstract][Full Text] [Related]
18. The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state.
Abdul-Fattah AM; Lechuga-Ballesteros D; Kalonia DS; Pikal MJ
J Pharm Sci; 2008 Jan; 97(1):163-84. PubMed ID: 17722086
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Protein-Excipient Microheterogeneity in Biopharmaceutical Solid-State Formulations by Confocal Fluorescence Microscopy.
Koshari SH; Ross JL; Nayak PK; Zarraga IE; Rajagopal K; Wagner NJ; Lenhoff AM
Mol Pharm; 2017 Feb; 14(2):546-553. PubMed ID: 28094996
[TBL] [Abstract][Full Text] [Related]
20. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.
Abdul-Fattah AM; Truong-Le V; Yee L; Nguyen L; Kalonia DS; Cicerone MT; Pikal MJ
J Pharm Sci; 2007 Aug; 96(8):1983-2008. PubMed ID: 17286290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
